Drug Safety and Pharmacovigilance 2020/2021 (7.5 credits)
Autumn 2020, Mixed, 50 %, Distance learning
Start date: 2 November 2020
End date: 17 January 2021
Application Deadline: 15 April 2020
Enrolment Code: UU-38501 Application
Language of Instruction: English
Location: Flexible
Selection: Higher education credits (maximum 285 credits)
Outline for distance course: The course is entirely web-based and contains no compulsory campus meetings. Lectures are recorded and organised as video/audio sessions and are available on a web-based teaching platform. The students are offered supervised studies via the same teaching platform. This platform is also used for individual assignments, group exercises and discussions. Some of these assignments and exercises are mandatory and the participants are offered general or individual feedback on these moments. The participants and teachers communicate via the website and via email. A forum for discussion is also available. Examination will be in the form of web-based tests or individual assignments. In order to participate in this course you must have access to a computer with a rapid Internet connection, headset with microphone and programs such as Adobe Flash/Connect have to be installed.
Spring 2021, Mixed, 50 %, Distance learning
Start date: 24 March 2021
End date: 6 June 2021
Application Deadline: 15 October 2020
Enrolment Code: UU-88501 Application
Language of Instruction: English
Location: Flexible
Selection: Higher education credits (maximum 285 credits)
Outline for distance course: The course is entirely web-based and contains no compulsory campus meetings. Lectures are recorded and organised as video/audio sessions and are available on a web-based teaching platform. The students are offered supervised studies via the same teaching platform. This platform is also used for individual assignments, group exercises and discussions. Some of these assignments and exercises are mandatory and the participants are offered general or individual feedback on these moments. The participants and teachers communicate via the website and via email. A forum for discussion is also available. Examination will be in the form of web-based tests or individual assignments. In order to participate in this course you must have access to a computer with a rapid Internet connection, headset with microphone and programs such as Adobe Flash/Connect have to be installed.
Entry Requirements: Adverse Drug Reactions and Pharmacovigilance, 7.5 credits, or at least 2.5 credits from Preclinical Safety Assessment and Pharmacovigilance. Within the Master of Science Programme in Pharmacy 150 credits within the programme are also required, as well as attendance of all courses in semesters 1-7.
Fees:
If you are not a citizen of a European Union (EU) or European Economic Area (EEA) country, or Switzerland, you are required to pay application or tuition fees. Formal exchange students will be exempted from tuition fees, as well as the application fee. Read more about fees.
Application Fee: SEK 900
Tuition fee, first semester: SEK 18125
Tuition fee, total: SEK 18125
Please note: The course is given in collaboration with the Uppsala Monitoring Centre (UMC). UMC is responsible for the management of the WHO Programme for International Drug Monitoring and the WHO Global ICSR Database.
About the course:
This is a continuation course based on the same format as the introductory course (Preclinical Safety Assessment and Pharmacovigilance) but a more comprehensive textbook will be used. We will discuss the principles of benefit/risk profiling of drugs and the safe use of medicines. The course is suitable for those who want to work with adverse drug event reporting and drug safety.
We appreciate that you are considering an application to this course. Please make sure that you understand the general and course-specific entry requirements before you apply. You must have passed 2,5 credits in our introductory course Preclinical Safety Assessment and Pharmacovigilance (3FX011 or 3FX211) or the entire course Adverse Drug Reactions and Pharmacovigilance (3FX200) in order to be eligible for this continuation course.
The course will focus on
- Risk management and communication
- Adverse event reporting and methods in pharmacovigilance
- The importance of genetic variation for adverse drug reactions
- Serious adverse drug reactions
- Risk/benefit profiling of pharmaceutical drugs especially biologicals and vaccines as well as pharmaceuticals and genetic variation
More information
Contact
Department of Pharmaceutical Biosciences
Biomedicinskt centrum BMC, Husargatan 3
Box 591, 751 24 UPPSALA
Eva Brittebo
E-mail: eva.brittebo@farmbio.uu.se